If you’re wanting to build a strong portfolio, owning a few blue chips could be a good starting point.
Blue chips are generally large companies that have been operating for many years, have stable cash flows, and experienced management teams. This tends to make them lower risk options and a good foundation to build a portfolio from.
But which blue chip shares should you consider buying? Two that analysts rate highly are listed below:
CSL Limited (ASX: CSL)
The first blue chip ASX 200 share to look at is leading biotechnology company CSL.
It is the name behind the CSL Behring plasma therapies business and the Seqirus vaccine business. In addition, the company is in the process of acquiring Vifor Pharma for $16.4 billion.
Vifor Pharma has a focus on iron deficiency, nephrology, and cardio-renal therapies. It also has a research and development (R&D) pipeline that complements CSL’s existing R&D activities and should be supportive of long term growth.
Citi is bullish on the company and has a buy rating and $330.00 price target on its shares. It said:
With plasma collections now back to pre-pandemic levels, we expect the market to shift its focus to the strong underlying plasma product demand. This should lead to strength in the CSL share price.
Wesfarmers Ltd (ASX: WES)
Another ASX 200 blue chip share that could be a top option for investors is Wesfarmers.
It is the company behind retail brands such as Bunnings, Kmart, and Priceline Pharmacy, and a collection of chemicals businesses. Combined with its strong management team and equally strong balance sheet, which provides further M&A opportunities, the future looks bright for Wesfarmers.
Morgans certainly believes that to be the case. So much so, it has add rating with a price target of $58.40. It commented:
We continue to see WES as a long-term, core portfolio holding with a strong mix of businesses, highly regarded management team and a healthy balance sheet.
The post Analysts name 2 ASX 200 blue chip shares to buy appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now
See The 5 Stocks
*Returns as of July 7 2022
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Whatâs the outlook for ASX 200 dividend shares in FY23?
- 5 worst ASX energy shares of FY22
- Here’s how ASX healthcare shares performed in FY22
- Analysts name 2 excellent ASX dividend shares for income investors to buy
- Beating the benchmark: Why this broker is betting on the CSL share price for outperformance
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has positions in and has recommended Wesfarmers Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/YskL7uS